Mechanisms of platinum drug resistance
Mechanisms of platinum drug resistance
复制标题
DOI：
10.1016/j.tips.2005.01.002
复制
发表时间：
2005-03-01
影响因子：
13.8
通讯作者：
Murata, Y
中科院分区：
文献类型：
--
作者：
Ohmichi, M;Hayakawa, J;Murata, Y
铂类药物是最有效的抗癌药物之一，广泛用于治疗各种人类实体瘤。虽然患者对铂类药物的反应率很高，但大多数患者在治疗期间对这些药物产生耐药性。由于获得耐药性是临床使用铂类药物的主要障碍，因此细胞产生这种耐药性的过程引起了极大的兴趣，并且已经做出努力来克服这个问题。丝裂原活化蛋白激酶（MAPK）和磷脂酰肌醇3-激酶（PI 3 K）级联都参与了这些药物的耐药性，一些小分子MAPK和PI 3 K-Akt级联抑制剂克服铂类药物耐药性的临床试验正在进行中。
Platinum-based drugs are among the most active anticancer agents available and are used widely for the treatment of a variety of human solid tumors. Although patients show high response rates to platinum drugs, most patients develop resistance to these drugs during treatment. Because the acquisition of resistance is a major obstacle to the clinical use of platinum drugs, the processes by which cells develop such resistance are of great interest and efforts have been made to overcome this problem. Both mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) cascades are involved in resistance to these drugs, and clinical trials of some small-molecule inhibitors of the MAPK and PI3K-Akt cascades to overcome resistance to platinum drugs are ongoing.